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Abstract
We introduce a novel data-driven framework for the design of targeted gene panels
for estimating exome-wide biomarkers in cancer immunotherapy. Our first goal is to
develop a generative model for the profile of mutation across the exome, which allows
for gene- and variant type-dependent mutation rates. Based on this model, we then
propose a new procedure for estimating biomarkers such as Tumour Mutation Burden
and Tumour Indel Burden. Our approach allows the practitioner to select a targeted
gene panel of a prespecified size, and then construct an estimator that only depends
on the selected genes. Alternatively, the practitioner may apply our method to make
predictions based on an existing gene panel, or to augment a gene panel to a given
size. We demonstrate the excellent performance of our proposal using an annotated
mutation dataset from 1144 Non-Small Cell Lung Cancer patients.
Keywords: cancer, gene panel design, targeted sequencing, tumour indel
burden, tumour mutation burden.
1 Introduction
It has been understood for a long time that cancer, a disease occurring in many distinct
tissues of the body and giving rise to a wide range of presentations, is initiated and driven
by the accumulation of mutations in a subset of a person’s cells (Boveri, 2008). Since the
discovery of Immune Checkpoint Blockade (ICB)1 (Ishida et al., 1992; Leach et al., 1996),
there has been an explosion of interest in cancer therapies targeting immune response and
ICB therapy is now widely used in clinical practice (Robert, 2020). ICB therapy works by
targeting natural mechanisms (or checkpoints) that disengage the immune system, for exam-
ple the proteins Cytotoxic T Lymphocyte Associated protein 4 (CTLA-4) and Programmed
Death Ligand 1 (PD-L1) (Buchbinder and Desai, 2016). Inhibition of these checkpoints can
promote a more aggressive anti-tumour immune response (Pardoll, 2012), and in some pa-
tients this leads to long-term remission (Gettinger et al., 2019). However, ICB therapy is
not always effective (Nowicki et al., 2018) and may have adverse side-effects, so determining
which patients will benefit in advance of treatment is vital.
Exome-wide prognostic biomarkers for immunotherapy are now well-established – in par-
ticular, Tumour Mutation Burden (TMB) is used to predict response to immunotherapy
1For their work on ICB, James Allison and Tasuku Honjo received the 2018 Nobel Prize for Physiol-

























(Zhu et al., 2019; Cao et al., 2019). TMB is defined as the total number of non-synonymous
mutations occurring throughout the tumour exome, and can be thought of as a proxy for
how easily a tumour cell can be recognised as foreign by immune cells (Chan et al., 2019).
However, the cost of measuring TMB using Whole Exome Sequencing (WES) (Sboner et al.,
2011) currently prohibits its widespread use as standard-of-care. Sequencing costs, both
financial and in terms of the time taken for results to be returned, are especially problematic
in situations where high-depth sequencing is required, such as when utilising blood-based
Circulating Tumour DNA (ctDNA) from liquid biopsy samples (Gandara et al., 2018). The
same issues are encountered when measuring more recently proposed biomarkers such as
Tumour Indel Burden (TIB) (Wu et al., 2019b; Turajlic et al., 2017), which counts the
number of frameshift insertion and deletion mutations. There is, therefore, demand for cost-
effective approaches to estimate these biomarkers (Fancello et al., 2019; Golkaram et al.,
2020).
In this paper we propose a novel, data-driven method for biomarker estimation, based on
a generative model of how mutations arise in the tumour exome. More precisely, we model
mutation counts as independent Poisson variables, where the mean number of mutations
depends on the gene of origin and variant type, as well as the Background Mutation Rate
(BMR) of the tumour. Due to the ultrahigh-dimensional nature of sequencing data and the
fact that in many genes mutations arise purely according to the BMR, we use a regularisation
penalty when estimating the parameters of the model. In addition, this identifies a subset
of genes that are mutated above or below the background rate. Our model facilitates the
construction of a new estimator of TMB, based on a weighted linear combination of the
number of mutations in each gene. The vector of weights is chosen to be sparse (i.e. have
many entries equal to zero), so that our estimator of TMB may be calculated using only
the mutation counts in a subset of genes. In particular, this allows for accurate estimation
of TMB from a targeted gene panel, where the panel size (and therefore the cost) may
be determined by the user. We demonstrate the excellent practical performance of our
framework using a Non-Small Cell Lung Cancer (NSCLC) dataset (Chalmers et al., 2017),
and include a comparison with existing state-of-the-art approaches for estimating TMB.
Moreover, since our model allows variant type-dependent mutation rates, it can be adapted
easily to predict other biomarkers, such as TIB. Finally, our method may also be used in
combination with an existing targeted gene panel. In particular, we can estimate a biomarker
directly from the panel, or first augment the panel and then construct an estimator.
Due to its emergence as a biomarker for immunotherapy in recent years, a variety of
groups have considered methods for estimating TMB. A simple and common way to esti-
mate TMB is via the proportion of mutated codons in a targeted region. Budczies et al.
(2019) investigate how the accuracy of predictions made in this way are affected by the size
of the targeted region, where mutations are assumed to occur at uniform rate throughout the
genome. More recently Yao et al. (2020) modelled mutations as following a negative binomial
distribution while allowing for gene-dependent rates, which are inferred by comparing non-
synonymous and synonymous mutation counts. In contrast, our method does not require
data including synonymous mutations. Where they are included, we do not assume that
synonymous mutations occur at a uniform rate throughout the genome, giving us the flexi-
bility to account for location-specific effects on synonymous mutation rate such as chromatin
configuration (Makova and Hardison, 2015) and transcription-dependent repair mechanisms
(Fong et al., 2013). Linear regression models have been used for both panel selection (Lyu
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et al., 2018) and for biomarker prediction (Guo et al., 2020). A review of some of the issues
arising when dealing with targeted panel-based predictions of TMB biomarkers is given by
Wu et al. (2019a). Finally, we are unaware of any methods for estimating TIB from targeted
gene panels.
The remainder of the paper is as follows. In Section 2, we introduce our data sources,
and provide a detailed description of our methodological proposal. Experimental results
are given in Section 3 and we conclude in Section 4. Finally, we also provide an R package
ICBioMark (Bradley and Cannings, 2021) which implements the methodology and reproduces
the experimental results in the paper.
2 Methodology
2.1 Data and terminology
Our methodology can be applied to any annotated mutation dataset obtained by WES. To
demonstrate our proposal we make use of the NSCLC dataset produced by Campbell et al.
(2016), which contains data from 1144 patient-derived tumours. For each sample in this
dataset we have the genomic locations and variant types of all mutations identified. At the
time of the study, the patients had a variety of prognoses and smoking histories, were aged
between 39 and 90, 41% were female and 59% were male; see Figure 1. In Figure 2A we
see that mutations counts are distributed over a very wide range, as is the case in many
cancer types (Chalmers et al., 2017). For simplicity, we only consider seven nonsynonymous
variant types: missense mutations (which are the most abundant), nonsense mutations,
frameshift insertions/deletions, splice site mutations, in-frame insertions/deletions, nonstop
mutations and translation start site mutations. We present the frequencies of these mutation
types in Figure 2B. Frameshift insertion/deletion (also known as indel) mutations are of
particular interest when predicting TIB, but contribute only a small proportion (< 4%) of
nonsynonymous mutations.
Figure 1: Demographic data for the clinical cohort in Campbell et al. (2016). A: Violin plots
of age for patients, stratified by sex. B: Stacked bar chart of patients’ smoking histories,
shaded according to cancer stage diagnosis.
It is useful at this point to introduce the notation used throughout the paper. The set
G denotes the collection of genes that make up the exome. For a gene g ∈ G, let `g be the
3
Figure 2: Dataset-wide distribution of mutations. A: Violin plot of the distribution of TMB
and TIB across training samples. B: The relative frequency of different nonsynonymous
mutation types.
length of g in nucleotide bases, defined by the maximum coding sequence2. A gene panel
is a subset P ⊆ G, and we write `P :=
∑
g∈P `g for its total length. We let S denote the
set of variant types in our data (e.g. in the dataset mentioned above, S contains the seven
possible non-synonymous variants). Now, for i = 0, 1, . . . , n, let Migs denote the count of
mutations in gene g ∈ G of type s ∈ S in the ith sample. Here the index i = 0 is used
to refer to an unseen test sample for which we would like to make a prediction, while the
indices i = 1, . . . , n enumerate the samples in our training data set. In order to define the








for i = 0, . . . , n. For example, including all non-synonymous mutation types in S̄ specifies
TiS̄ as the TMB of sample i, whereas letting S̄ contain only indel mutations gives TIB.
Our main goal is to predict T0S̄ based on {M0gs : g ∈ P, s ∈ S}, where the panel P ⊆ G
has length `P satisfying some upper bound. When it is clear from context that we are
referring to the test sample and a specific choice of biomarker (i.e. S̄ is fixed), we will simply
write T in place of T0S̄.
2.2 Generative model
We now describe the main statistical model that underpins our methodology. In order
to account for selective pressures and other factors within the tumour, we allow the rate at
which mutations occur to depend on the gene and type of mutation. Our model also includes
a sample-dependent parameter to account for the differing levels of mutagenic exposure of
tumours, which may occur due to exogenous (e.g. UV light, cigarette smoke) or endogenous
(e.g. inflammatory, free radical) factors.
2The maximum coding sequence is defined as the collection of codons that may be translated for some
version of a gene, even if all the codons comprising the maximum coding sequence are never simultaneously
translated. Gene coding lengths are extracted from the Ensembl database (Yates et al., 2020).
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We model the mutation counts Migs as independent Poisson random variables with mu-
tation rates φigs > 0. More precisely, for i = 0, 1, . . . , n, g ∈ G and s ∈ S, we have
Migs ∼ Poisson(φigs), (2)
where Migs and Mi′g′s′ are independent for (i, g, s) 6= (i′, g′, s′). Further, to model the
dependence of the mutation rate on the sample, gene and mutation type, we use a log-link
function and let
log(φigs) = µi + log(`g) + λg + νs + ηgs, (3)
for µi, λg, νs, ηgs ∈ R, where for identifiability we set ηgs1 = 0, for some s1 ∈ S and all g ∈ G.
The terms in our model can be interpreted as follows. First, the parameter µi corresponds
to the BMR of the ith sample. The offset log(`g) accounts for a mutation rate that is
proportional to the length of a gene, so that a non-zero value of λg corresponds to increased
or decreased mutation rate relative to the BMR. The parameters νs and ηgs account for
differences in frequency between mutation types for each gene.
The model in (2) and (3) (discounting the unseen test sample i = 0) has n+ |S|+ |G||S|
free parameters and we have n|G||S| independent observations in the training data set. In
principle we could attempt to fit our model directly using maximum likelihood estimation.
However, we wish to exploit the fact that most genes do not play an active role in the
development of a tumour, and will be mutated approximately according to the BMR. This
corresponds to the parameters λg and ηgs being zero for many g ∈ G. We therefore include
an `1-penalisation term applied to the parameters λg and ηgs when fitting our model. We
do not penalise the parameters νs or µi.
Writing µ := (µ1, . . . , µn), λ := (λg : g ∈ G), ν := (νs : s ∈ S) and η := (ηgs : g ∈ G, s ∈
S), and given training observations Migs = migs, we let








φigs −migs log φigs
)
be the negative log-likelihood of the model specified by (2) and (3). We then define
(µ̂, λ̂, ν̂, η̂) = arg min
µ,λ,ν,η
{











where κ1 ≥ 0 is a tuning parameter that controls the number of non-zero components in λ̂
and η̂, which we choose using cross-validation (see Section 2.5 for more detail).
2.3 Proposed estimator
We now attend to our main goal of estimating a given exome-wide biomarker for the unseen
test sample. Fix S̄ ⊆ S and recall that we write T = T0S̄. We wish to construct an estimator
of T that only depends on the mutation counts in a gene panel P ⊂ G, subject to a constraint








3Note that our estimator may use the the full set S of variant types, rather than just those in S̄. In other
words, our estimator may utilise information from every mutation type, not just those that directly constitute
the biomarker of interest. This is important when estimating mutation types in S̄ that are relatively scarce
(e.g. for TIB).
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for w ∈ R|G|×|S|. In the remainder of this subsection we explain how the weights w are
chosen to minimise the expected squared error of T (w) based on the generative model in
Section 2.2.
Of course, setting wgs = 1 for g ∈ G and s ∈ S̄ (and wgs = 0 otherwise) will give
T (w) = T . However, our aim is to make predictions based on a concise gene panel. If,
for a given g ∈ G, we have wgs = 0 for all s ∈ S, then T (w) does not depend on the
mutations in g and therefore the gene does not need to be included in the panel. In order to
produce a suitable gene panel (i.e. with many wgs = 0), we penalise non-zero components of
w when minimising the expected squared error. We define our final estimator via a refitting
procedure, which improves the predictive performance by reducing the bias, and is also
helpful when applying our procedure to panels with predetermined genes.
To construct our estimator, note that under our model in (2) we have EM0gs = Var(M0gs) =

































This depends on the unknown parameters µ0, λg, νs and ηgs, the latter three of which are
replaced by their estimates given in (4). It is also helpful to then rescale (5) as follows: write







`g exp(λ̂g + ν̂s + η̂gs)∑
g′∈G
∑





























s∈S̄ `g exp(λ̂g + ν̂s + η̂gs). Since f is a rescaled version of
the error in (5) (with the true parameters λ, ν, η replaced by the estimates λ̂, ν̂, η̂), we will
choose w to minimise f(w).
Note that f only depends on µ0 via the K(µ0) term, which can be interpreted as a penalty
factor controlling the bias of our estimator. For example, we may insist that the squared





2 is zero by setting K(µ0) = ∞. In practice, we propose
to choose the penalty K based on the training data; see Section 2.5.
At this point f(w) is minimised by choosing w to be such that wgs = 1 for all g ∈ G, s ∈ S̄,
and wgs = 0 otherwise. As mentioned above, in order to form a concise panel while optimising
predictive performance, we impose a constraint on the cost of sequencing the genes used in




`g1{wgs 6= 0 for some s ∈ S}.
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This choice acknowledges that the cost of a panel is roughly proportional to the length of
the region of genomic space sequenced, and that once a gene has been sequenced for one
mutation type there is no need to sequence again for other mutation types.
Now, given a cost restriction L, our goal is to minimise f(w) such that ‖w‖G,0 ≤ L.
In practice this problem is non-convex and so computationally infeasible. As is common
in high-dimensional optimisation problems, we consider a convex relaxation as follows: let
‖w‖G,1 :=
∑
g∈G `g‖wg‖2, where wg = (wgs : s ∈ S) ∈ R|S|, for g ∈ G, and ‖ · ‖2 is the
Euclidean norm. Define






where κ2 ≥ 0 is chosen to determine the size of the panel selected.
The final form of our estimator is obtained by a refitting procedure. First, for P ⊆ G,
let
WP := {w ∈ R|G|×|S| : wg = (0, . . . , 0) for g ∈ G \ P}. (7)
Let P̂ := {g ∈ G : ‖ŵfirst-fitg ‖2 > 0} be the panel selected by the first-fit estimator in (6),
and define






We then estimate T using T̂ := T (ŵrefit), which only depends on mutations in genes contained
in the selected panel P̂ . The performance of our estimator is investigated in Section 3, for
comparison we also include the performance of the first-fit estimator T (ŵfirst−fit).
2.4 Panel augmentation
In practice, when designing gene panels a variety of factors contribute to the choice of genes
included. For example, a gene may be included due to its relevance to immune response or its
known association with a particular cancer type. If this is the case, measurements for these
genes will be made regardless of their utility for predicting exome-wide biomarkers. When
implementing our methodology, therefore, there is no additional cost to incorporate observa-
tions from these genes into our prediction if they will be helpful. Conversely researchers may
wish to exclude genes from a panel, or at least from actively contributing to the estimation
of a biomarker, for instance due to technical difficulties in sequencing a particular gene.
We can accommodate these restrictions by altering the structure of our regularisation
penalty in (6). Suppose we are given (disjoint sets of genes) P0, Q0 ⊆ G to be included and
excluded from our panel, respectively. In this case, we replace ŵfirst-fit in (6) with









Excluding the elements of P0 from the penalty term means that ŵ
first-fit
P0,Q0
6= 0 for the genes
in P0, while restricting our optimisation to WG\Q0 excludes the genes in Q0 by definition.
This has the effect of augmenting the predetermined panel P0 with additional genes selected
to improve predictive performance. We then perform refitting as described above. We
demonstrate this procedure by augmenting the TST-170 gene panel in Section 3.4.
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2.5 Practical considerations
In this section, we discuss some practical aspects of our proposal. Our first consideration
concerns the choice of the tuning parameter κ1 in (4). As is common for the Least Absolute
Shrinkage and Selection Operator (LASSO) estimator in generalised linear regression (see,
for example, Michoel (2016) and Friedman et al. (2020)), we will use 10-fold cross-validation.
To highlight one important aspect of our cross-validation procedure, recall that we consider
the observations Migs as independent across the sample index i ∈ {1, . . . , n}, the gene
g ∈ G and the mutation type s ∈ S. Our approach therefore involves splitting the entire set
{(i, g, s) : i = 1, . . . , n, g ∈ G, s ∈ S} of size n|G||S| (as opposed to the sample set {1, . . . , n})
into 10 folds uniformly at random. We then apply the estimation method in (4) to each of
the 10 folds separately on a grid of values (on the log scale) of κ1, and select the value that
results in the smallest average deviance across the folds. The model is then refitted using
all the data for this value of κ1.
The estimated coefficients in (6) depend on the choice of K(µ0) and κ2. As mentioned
above, we could set K(µ0) =∞ to give an unbiased estimator, however in practice we found
that a finite choice of K(µ0) leads to improved predictive performance. Our recommendation
is to use K(µ0) = K(maxi=1,...,n{µ̂i}), where µ̂i = log(Ti/
∑
g,s `g exp(λ̂g + ν̂s + η̂gs)) is a
pseudo-MLE (in the sense of Gong and Samaniego (1981)) for µi, so that the penalisation
is broadly in proportion with the largest values of µi in the training dataset. The tuning
parameter κ2 controls the size of the gene panel selected in (6): given a panel length L, we
set κ2(L) = max{κ2 : `P̂ ≤ L} in order to produce a suitable panel.
We now comment briefly on some computational aspects of our method. The generative
model fit in (4) can be solved via coordinate descent (see, for example, Friedman et al., 2010),
which has a computational complexity of O(N |G|2|S|2) per iteration. We fit the model 10
times, one for each fold in our cross-validation procedure. This is the most computationally
demanding part of our proposal – in our experiments below, it takes approximately an hour
to solve on a standard laptop – but it only needs to be carried out once for a given dataset.
The convex optimisation problem in (6) can be solved by any method designed for the group
LASSO; see, for example, Yang and Zou (2015). In our experiments in Section 3, we use the
gglasso R package (Yang et al., 2020), which takes around 10 minutes to reproduce the plot
in Figure 6. Note also that the solutions to (6) and (8) are unique; see, for example, Roth
and Fischer (2008, Theorem 1). The last step of our proposal, namely making predictions
for new test observations based on a selected panel, carries negligible computational cost.
Finally we describe a heuristic procedure for producing prediction intervals around our
point estimates. In particular, for a given confidence level α ∈ (0, 1), we aim to find an
interval [T̂L, T̂U] such that P
(
T̂L ≤ T ≤ T̂U
)
≥ 1− α. To that end, let tα := E{(T̂ − T )2}/α,
then by Markov’s inequality we have that P(|T̂ −T |2 ≥ tα) ≤ α. It follows that [T̂ − t1/2α , T̂ +
t
1/2
α ] is a (1 − α)-prediction interval for T . Of course, the mean squared error E{(T̂ − T )2}
defined in (5) depends on the parameters λ, η, ν and µ0, which are unknown. Our approach is
to utilise the estimates λ̂, η̂, ν̂ (see (4)) and replace µ0 with log(T̂ /
∑
g,s `g exp(λ̂g+ ν̂s+ η̂gs)).
While this is not an exact (1− α)-prediction interval for T , we will see in our experimental




In this section we demonstrate the practical performance of our proposal using the dataset
from Campbell et al. (2016), which we introduced in Section 2.1. Our main focus is the pre-
diction of TMB, and we show that our approach outperforms the state-of-the-art approaches.
We also analyse the suitability of our generative model, consider the task of predicting the
recently proposed biomarker TIB, and include a panel augmentation case study with the
Foundation One gene panel.
Since we are only looking to produce estimators for TMB and TIB, we group mutations
into two categories – indel mutations and all other non-synonymous mutations – so that
|S| = 2. This simplifies the presentation of our results and reduces the computational cost
of fitting the generative model. In order to assess the performance of each of the methods
in this section, we randomly split the dataset into training, validation and test sets, which
contain ntrain = n = 800, nval = 171 and ntest = 173 samples, respectively. Mutations are
observed in |G| = 17358 genes. Our training set comprises samples with an average TMB of
252 and TIB of 9.25.
3.1 Generative model fit and validation
The first step in our analysis is to fit the model proposed in Section 2.2 using only the training
dataset. In particular, we obtain estimates of the model parameters using equation (4),
where the tuning parameter κ1 is determined using 10-fold cross-validation as described in
Section 2.5. The results are presented in Figure 3. The best choice of κ1 produces estimates of
λ and η with 44.4% and 77.8% sparsity respectively, i.e. that proportion of their components
are estimated to be exactly zero. We plot λ̂ and η̂ for this value of κ1 in Figures 4 and 5.
Genes with λ̂g = 0 are interpreted to be mutating according to the background mutation
rate, and genes with η̂g,indel = 0 are interpreted as having no specific selection pressure for
or against indel mutations. In Figures 4 and 5 we highlight genes with large (in absolute
value) parameter estimates, some of which have known biological relevance in oncology; see
Section 4 for further discussion.
Figure 3: The average deviance (with one standard deviation) across the 10 folds in our cross-
validation procedure plotted against log(κ1). The minimum average deviance is highlighted
red.
We now validate our model in (3) by comparing with the following alternatives:
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Figure 4: Manhattan plot of fitted parameters λ̂g and their associated genes’ chromosomal
locations. The genes with the five largest positive parameter estimates are labelled.
Figure 5: Manhattan plot of fitted parameters η̂g,indel and their associated genes’ chromoso-
mal locations. The five largest positive and negative genes are labelled.
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(i) Saturated model : the model in (2), where each observation has an associated free
parameter (i.e. φigs > 0 is unrestricted);
(ii) No sample-specific effects : the model in (3), with µi = 0 for all i ∈ {1, . . . , n};
(iii) No gene-specific effects : the model in (3), with λg = ηgs = 0 for all g ∈ G and s ∈ S;
(iv) No gene/mutation type interactions : the model in (3), with ηgs = 0 for all g ∈ G and
s ∈ S.
In Table 1 we present the residual deviance and the residual degrees of freedom between
our model and each of the models above. We see that our model is preferred over the
saturated model, and all three submodels of (3).
Table 1: Model comparisons on the basis of residual deviance statistics.
Comparison Residual Residual Degrees dev/df p-value
Model Deviance (dev) of Freedom (df)
(i) 1.43× 106 2.74× 107 5.22× 10−2 1.00
(ii) 1.42× 105 8.00× 102 1.77× 102 0.00
(iii) 1.10× 105 1.33× 104 8.24× 100 0.00
(iv) 1.70× 104 1.82× 103 9.33× 100 0.00
3.2 Predicting tumour mutation burden
We now demonstrate the excellent practical performance of our procedure for estimating
TMB. First it is shown that our method can indeed select gene panels of size specified by
the practitioner and that good predictions can be made even with small panel sizes (i.e. ≤
1Mb). We then compare the performance of our proposal with state-of-the-art estimation
procedures based on a number of widely used gene panels.
In order to evaluate the predictive performance of an estimator we calculate the R2 score
on the validation data as follows: given predictions of TMB, t̂1, . . . , t̂nval , for the observations




i=1 ti, and define
R2 := 1−
∑nval
i=1 (ti − t̂i)2∑nval
i=1 (ti − t̄)2
.
Other existing works have aimed to classify tumours into two groups (high TMB, low
TMB); see, for example, Büttner et al. (2019) and Wu et al. (2019a). Here we also report
the estimated area under the precision-recall curve (AUPRC) for a classifier based on our
estimator. We define the classifier as follows: first, in line with major clinical studies (e.g.
Hellmann et al., 2018; Ramalingam et al., 2018) the true class membership of a tumour
is defined according to whether it has t∗ := 300 or more exome mutations (approximately
10 Mut/Mb). In the validation set, this gives 47 (27.5%) tumours with high TMB and
124 (72.5%) with low TMB. Now, for a cutoff t ≥ 0, we can define a classifier by assigning a
tumour to the high TMB class if its estimated TMB value is greater than or equal to t. For











respectively. The precision-recall curve then is {(r(t), p(t)) : t ∈ [0,∞)}. Note that a perfect
classifier achieves a AUPRC of 1, whereas a random guess in this case would have an average
AUPRC of 0.308 (the prevalence of the high TMB class).
Now recall that TMB is given by equation (1) with S̄ being the set of all non-synonymous
mutation types. Thus to estimate TMB we apply our procedure in Section 2.3 with S̄ = S,
where the model parameters are estimated as described in Section 3.1. In Figure 6, we
present the R2 and AUPRC for the first-fit and refitted estimators (see (6) and (8)) as the
selected panel size varies from 0Mb to 2Mb in length. We see that we obtain a more accurate
prediction of TMB, both in terms of regression and classification, as the panel size increases,
and that good estimation is possible even with very small panels (as low as 0.2Mb). Finally,
as expected, the refitted estimator slightly outperforms the first-fit estimator.
Figure 6: Performance of our first-fit and refitted estimators of TMB as the selected panel
size varies. Left: R2, Right: AUPRC.
We now compare our method with state-of-the-art estimators applied to commonly used
gene panels. The three next-generation sequencing panels that we consider are chosen for
their relevance to TMB. These are TST-170 (Heydt et al., 2018), Foundation One (Frampton
et al., 2013) and MSK-IMPACT (Cheng et al., 2015). For each panel P ⊆ G, we use four
different methods to predict TMB:
(i) Our refitted estimator applied to the panel P : we estimate TMB using T (ŵP ), where
ŵP ∈ arg minw∈WP {f(w)}, and WP is defined in (7).
(ii) Estimation and Classification of Tumour Mutation Burden (ecTMB): the procedure
proposed by Yao et al. (2020).





s∈S̄M0gs, i.e. rescaling the muta-
tion burden in the genes of P .
(iv) A linear model: we estimate TMB via ordinary least-squares linear regression of TMB
against
{∑
s∈SM0gs : g ∈ P
}
.
The latter three comprise existing methods for estimating TMB available to practitioners.
The second (ecTMB), which is based on a negative binomial model, is the state-of-the-art.
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The third and fourth are standard practical procedures for the estimation of TMB from
targeted gene panels. The refitted estimator applied to the panel P is also included here, in
order to demonstrate the utility of our approach even with a prespecified panel.
Figure 7: The performance of our TMB estimator in comparison to existing approaches.
Left: R2, Right: AUPRC.
We present results of these comparisons in Figure 7. First, for each of the three pan-
els considered here, we see that our refitted estimator applied to the panel outperforms all
existing approaches in terms of regression performance, and that for smaller panels we are
able to improve regression accuracy even further by selecting a panel based on the training
data. For instance, in comparison to predictions based on the TST-170 panel, our procedure
with a selected panel of the same size (0.4Mb) achieves an R2 of 0.85. The best available
existing method based on the TST-170 panel, in this case the linear estimator, has an R2 of
0.74. Moreover, data-driven selection of panels considerably increases the classification per-
formance for the whole range of panel sizes considered. In particular, even for the smallest
panel size shown in Figure 7 (∼0.2Mb), the classification performance of our method out-
performs the best existing methodology applied to the MSK-IMPACT panel, despite being
almost a factor of six times smaller.
Finally in this section we demonstrate the practical performance of our method using
the test set, which until this point has been held out. Based on the validation results above,
we take the panel of size 0.6Mb selected by our procedure and use our refitted estimator
on that panel to predict TMB for the 173 samples in the test set. For comparison, we
also present predictions from ecTMB, the count-based estimator and the linear regression
estimator applied to the same panel. In Figure 8 we see that our procedure performs well;
we obtain an R2 value (on the test data) of 0.85. The other methods have R2 values of 0.67
(ecTMB), −36 (count) and 0.64 (linear regression). The count-based estimator here gives
predictions which are reasonably well correlated to the true values of TMB but are positively
biased. This is as expected, since our selection procedure tends to favour genes with higher
overall mutation rates. We also include a red shaded region comprising all points for which
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heuristic 90% prediction intervals (as described in Section 2.5) include the true TMB value.
We find in this case that 93.6% of the observations in the test set fall within this region,
giving valid empirical coverage.
Figure 8: Prediction of TMB on the test dataset. Dashed blue (diagonal) line represents
perfect prediction, and the black dashed lines indicate true and predicted TMB values of
300.
3.3 Predicting tumour indel burden
In this section we demonstrate how our method can be used to estimate TIB. This is more
challenging than estimating TMB due to the low abundance of indel mutations relative to
other variant types (see Figure 2), as well as issues involved in sequencing genomic loci
of repetitive nucleotide constitution (Narzisi and Schatz, 2015). Indeed, in contrast to the
previous section, we are not aware of any existing methods designed to estimate TIB from
targeted gene panels. We therefore investigate the performance of our method across a much
wider range (0-30Mb) of panel sizes, and find that we are able to accurately predict TIB
with larger panels. Our results also demonstrate that accurate classification of TIB status
is possible even with small gene panels.
We let Sindel be the set of all frameshift insertion and deletion mutations, and apply our
method introduced in Section 2.3 with S̄ = Sindel. As in the previous section, we assess
regression and classification performance via R2 and AUPRC, respectively, where in this
case tumours are separated into two classes: high TIB (10 or more indel mutations) and low
TIB (otherwise). In the validation dataset, this gives 57 (33.3%) tumours in the high TIB
class.
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Figure 9: Performance of our first-fit and refitted estimators of TIB as the selected panel
size varies. Left: R2, Right: AUPRC.
The results are presented in Figure 9. We comment first on the regression performance:
as expected, we see that the R2 values for our first-fit and refitted estimators are much lower
than what we achieved in estimating TMB. The refitted approach improves for larger panel
sizes, while the first-fit estimator continues to perform relatively poorly. On the other hand,
we see that the classification performance is impressive, with AUPRC values of above 0.8
for panels of less than 1Mb in size.
We now assess the performance on the test set of our refitted estimator of TIB applied
to a selected panel of size 0.6Mb, and we compare with a count-based estimator and linear
regression estimator. We do not compare with ecTMB here, since it is designed to estimate
TMB as opposed to TIB. The count-based estimator in this case scales the total number
of non-synonymous mutations across the panel by the ratio of the length of the panel to
that of the entire exome, and also by the relative frequency of indel mutations versus all



















In Figure 10 we present the predictions on the test set of our refitted estimator (R2 = 0.35);
the count estimator (R2 = −44); and the linear regression estimator (R2 = 0.15). We also
include (shaded in red) the set of points for which 90% prediction intervals contain the true
value. In this case we find that 97.7% of test set points fall within this region.
3.4 A panel-augmentation case study
As discussed in Section 2.4, we may wish to include genes from a given panel, but use our
methodology to augment the panel to include additional genes with goal of obtaining more
accurate predictions of TMB (or other biomarkers). In this section we demonstrate how this
can be done starting with the TST-170 panel (∼0.4Mb) and augmenting to 0.6Mb in length,
demonstrating impressive gains in predictive performance.
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Figure 10: Estimation of TIB on the test dataset. Dashed blue (diagonal) line represents
perfect prediction, and the grey dashed lines indicate true and predicted TIB values of 10.
We apply the augmentation method described in Section 2.4, with P0 taken to be the
set of TST-170 genes and Q0 to be empty. The genes added to the panel are determined
by the first-fit estimator in equation (9). To evaluate the performance, we then apply the
refitted estimator on the test dataset, after selecting the augmented panel of size 0.6Mb. For
comparison, we apply our refitted estimator to the TST-170 panel directly. We also present
the results obtained by the other estimators described above, both before and after the panel
augmentation, in Table 2. We find that by augmenting the panel we improve predictive
performance with our refitted T̂ estimator, both in terms of regression and classification.
The refitted estimator provides better estimates than any other model on the augmented
panel by both metrics.
Table 2: Predictive performance of models on TST-170 (0.4Mb) versus augmented TST-170
(0.6Mb) panels on the test set.
Model
Regression (R2) Classification (AUPRC)
TST-170 Aug. TST-170 TST-170 Aug. TST-170
Refitted T̂ 0.58 0.84 0.83 0.94
ecTMB 0.37 0.51 0.80 0.88
Count 0.18 0.18 0.83 0.94
Linear 0.47 0.74 0.78 0.89
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4 Conclusions
We have introduced a new data-driven framework for designing targeted gene panels which
allows for cost-effective estimation of exome-wide biomarkers. Using the Non-Small Cell
Lung Cancer dataset from Campbell et al. (2016), we have demonstrated the excellent pre-
dictive performance of our proposal for estimating Tumour Mutation Burden and Tumour
Indel Burden, and shown that it outperforms the state-of-the-art procedures. Our framework
can be applied to any tumour dataset containing annotated mutations, and we provide an R
package (Bradley and Cannings, 2021) which implements the methodology.
Our work also has the scope to help understand mutational processes. For example, the
parameters of our fitted model in Section 3.1 have interesting interpretations: of the five
genes highlighted in Figure 4 as having the highest mutation rates relative to the BMR,
three (TP53, KRAS, CDKN2A) are known tumour suppressors (Olivier et al., 2010; Janč́ık
et al., 2010; Foulkes et al., 1997). Furthermore, indel mutations in KRAS are known to be
deleterious for tumour cells (Lee et al., 2018) – in our work the KRAS gene has a large
negative indel-specific parameter (see Figure 5). Our methodology identifies a number of
other genes with large parameter estimates.
Finally, we believe there are many ways in which our general framework can be extended.
For example, it may be adapted to incorporate alternate data types (e.g. transcriptomics);
we may seek to predict other features (e.g. outcomes such as survival); or we may wish to
extend the method to incorporate multiple data sources (e.g. on different cancer types and
tissues of origin).
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